PET影像组学能否预测局部晚期宫颈癌的病理肿瘤反应与预后
本研究回顾性分析2010年7月至2016年7月连续纳入的195例局部晚期宫颈癌患者,在 Nehoadjuvant 放化疗前行[18F]FDG PET/CT,提取原发肿瘤影像组学特征,评估其较常规PET参数和组织病理学特征能否更好预测病理反应和生存。结果显示所有参数曲线下面积均小于0.70,未进一步行回归分析,影像组学特征未能预测病理反应和生存。
要点
- 195例局部晚期宫颈癌患者中,67.2%为无或镜下残留(pR0/pR1),32.8%为肉眼残留(pR2)。
- 常规PET参数中仅SUVmean在病理反应者与无反应者间有显著差异。
- 影像组学特征中1个形状和3个纹理特征在反应者与无反应者间有显著差异。
核心结论
- 在大量接受新辅助放化疗后手术的局部晚期宫颈癌患者中,PET影像组学特征不能预测组织病理学肿瘤反应和生存。
- 作者认为,亟需进一步探索影像衍生参数的生物学机制,并规划大规模、前瞻性、多中心研究,采用标准化方案覆盖影像组学分析全过程,以在临床常规使用前验证影像组学。
研究设计与样本
- 回顾性审查2010年7月至2016年7月连续转诊的局部晚期宫颈癌患者病历。
- 在新辅助放化疗前行[18F]FDG PET/CT,从PET图像上半自动勾画的原发肿瘤体积中提取影像组学特征,并通过因子分析降维。
- 采用受试者工作特征分析,常规和影像组学特征按Liu法根据病理反应和癌症特异性死亡进行二分类。
- 按研究方案,仅选择曲线下面积大于0.70的参数进一步分析,包括用于反应预测的logistic回归分析和用于生存预测的Cox回归分析。
主要发现
- 共195例患者符合纳入标准;术后病理评估显示131例(67.2%)无或镜下(≤3 mm)残留肿瘤(分别为pR0或pR1),64例(32.8%)有肉眼残留肿瘤(>3 mm,pR2)。
- 中位随访76.0个月(95% CI,70.7-78.7个月),31.3%的患者出现复发或进展,20.0%死于该病。
- 常规PET参数中,SUVmean在病理反应者与无反应者间有显著差异。
- 影像组学特征中,1个形状特征和3个纹理特征在病理反应者与无反应者间有显著差异。
- 3个影像组学特征在有无复发或进展间以及有无癌症特异性死亡间有显著差异。
关键数值与推荐
- 病理反应定义:pR0为无残留肿瘤,pR1为镜下残留(≤3 mm),pR2为肉眼残留(>3 mm)。
- 参数筛选阈值:仅曲线下面积大于0.70者进入进一步回归分析。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study investigated whether radiomic features extracted from pretreatment [18F]FDG PET could improve the prediction of both histopathologic tumor response and survival in patients with locally advanced cervical cancer (LACC) treated with neoadjuvant chemoradiotherapy followed by surgery compared with conventional PET parameters and histopathologic features. Methods: The medical records of all consecutive patients with LACC referred between July 2010 and July 2016 were reviewed. [18F]FDG PET/CT was performed before neoadjuvant chemoradiotherapy. Radiomic features were extracted from the primary tumor volumes delineated semiautomatically on the PET images and reduced by factor analysis. A receiver-operating-characteristic analysis was performed, and conventional and radiomic features were dichotomized with Liu's method according to pathologic response (pR) and cancer-specific death. According to the study protocol, only areas under the curve of more than 0.70 were selected for further analysis, including logistic regression analysis for response prediction and Cox regression analysis for survival prediction. Results: A total of 195 patients fulfilled the inclusion criteria. At pathologic evaluation after surgery, 131 patients (67.2%) had no or microscopic (≤3 mm) residual tumor (pR0 or pR1, respectively); 64 patients (32.8%) had macroscopic residual tumor (>3 mm, pR2). With a median follow-up of 76.0 mo (95% CI, 70.7-78.7 mo), 31.3% of patients had recurrence or progression and 20.0% died of the disease. Among conventional PET parameters, SUVmean significantly differed between pathologic responders and nonresponders. Among radiomic features, 1 shape and 3 textural features significantly differed between pathologic responders and nonresponders. Three radiomic features significantly differed between presence and absence of recurrence or progression and between presence and absence of cancer-specific death. Areas under the curve were less than 0.70 for all parameters; thus, univariate and multivariate regression analyses were not performed. Conclusion: In a large series of patients with LACC treated with neoadjuvant chemoradiotherapy followed by surgery, PET radiomic features could not predict histopathologic tumor response and survival. It is crucial to further explore the biologic mechanism underlying imaging-derived parameters and plan a large, prospective, multicenter study with standardized protocols for all phases of the process of radiomic analysis to validate radiomics before its use in clinical routine.
引用
- Collarino A, Feudo V, Pasciuto T, et al. Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer? J Nucl Med. 2024. PMID: 38548352. doi:10.2967/jnumed.123.267044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。